Je veux savoir à propos de…

Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special Emphasis Panel; Early Phase Clinical Trials for Psychosocial Interventions.
Date: March 22, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 Telephone Conference Call.
Contact Person: Nicholas Gaiano, Ph.D., Review Branch Chief, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center/Room 6150/MSC 9606, 6001 Executive Boulevard, Bethesda, MD 208929606, 3014432742, nick.gaiano@nih.gov.
Name of Committee: National Institute of Mental Health Special Emphasis Panel; Role of Myeloid Cells in Brain HIV1 Reservoirs R01, R21.
Date: March 23, 2021.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852
Telephone Conference Call.
Contact Person: David W. Miller, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6140, MSC 9608, Bethesda, MD 208929608, 3014439734, millerda@mail.nih.gov.
Name of Committee: National Institute of Mental Health Special Emphasis Panel;
Suicide Prevention Centers.
Date: March 23, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 Telephone Conference Call.
Contact Person: Nicholas Gaiano, Ph.D., Review Branch Chief, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center/Room 6150/MSC 9606, 6001 Executive Boulevard, Bethesda, MD 208929606, 3014432742, nick.gaiano@nih.gov.
Name of Committee: National Institute of Mental Health Special Emphasis Panel;
BRAIN Initiative: Tools to Facilitate HighThroughput Microconnectivity Analysis R01.
Date: March 25, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive
VerDate Sep<11>2014

21:07 Feb 26, 2021

Jkt 253001

Boulevard, Rockville, MD 20852 Telephone Conference Call.
Contact Person: Erin E. Gray, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Boulevard, NSC 6152B, Bethesda, MD 20892, 3014028152, erin.gray@nih.gov.
Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS
Dated: February 23, 2021.
Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202104071 Filed 22621; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Asthma and Allergic Diseases Cooperative Research Centers U19
Clinical Trial Optional.
Date: March 2223, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G51, Rockville, MD 20892 Virtual Meeting.
Contact Person: Thomas F. Conway, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G51, Rockville, MD
20852, 2405079685, thomas.conway@
nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS

PO 00000

Frm 00091

Fmt 4703

Sfmt 4703

12009

Dated: February 22, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202104176 Filed 22621; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health Services Administration Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
AGENCY:

The Department of Health and Human Services HHS notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities IITFs currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine or Oral Fluid Mandatory Guidelines.
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B, Rockville, Maryland 20857; 240276
2600 voice; Anastasia.Donovan@
samhsa.hhs.gov email.
SUPPLEMENTARY INFORMATION: In accordance with Section 9.19 of the Mandatory Guidelines, a notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF
certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.
If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program NLCP
during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.
This notice is also available on the internet at https www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human Services HHS notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities IITFs currently certified to meet the standards of the Mandatory Guidelines for Federal SUMMARY:

E:FRFM01MRN1.SGM

01MRN1